<DOC>
	<DOCNO>NCT02135354</DOCNO>
	<brief_summary>This project ( funded IWT-TBM program ) organize randomize placebo-controlled multicenter intervention trial 500 COPD patient study effectiveness safety azithromycin therapy acute set COPD exacerbation require hospital admission . Although long-term use azithromycin proven effective prevent exacerbation , inherent risk outweigh benefit . By reduce dose duration azithromycin treatment restrict treatment acute period high risk treatment failure , benefit may counterbalance potential side effect , may result new treatment strategy acute event . The present study design service respiratory medicine Leuven Ghent University hospital run total 17 different large hospital Belgium , 12 locate Flanders .</brief_summary>
	<brief_title>Azithromycin Acute Exacerbations Requiring Hospitalization</brief_title>
	<detailed_description>In 9 month , randomize , placebo-controlled , parallel-group , multicenter intervention trial , 500 patient randomly assign ( 1:1 ratio ) receive either azithromycin placebo top standard therapy acute treatment COPD exacerbation require hospitalization . The study drug ( azithromycin placebo ) initiate uploaded within 48 hour hospital admission ( 500mg day 3 day ) subsequently administer prolonged period 3 month low maintenance dose ( 250mg every 2 day ) . An additional follow-up period 6 month without study drug foreseen study relapse study drug withdrawal .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Established diagnosis COPD medical doctor ( base clinical history OR pulmonary function test ) Smoking history least 10 packyears ( 10 packyears define 20 cigarette day 10 year , 10 cigarette day 20 year , etc . ) Current hospitalization potential infectious AECOPD treat standard therapy History least one exacerbation last year ( prior current hospital admission ) systemic steroid and/or antibiotic take ECG admission Mechanical noninvasive ventilation moment randomization ( D1 ) Long QT interval ECG ( QTc &gt; 450msec male &gt; 470msec female ) History lifethreatening arrhythmias Myocardial infarction ( NSTEMI STEMI ) less 6 week start study drug Unstable angina pectoris acute myocardial infarction ( NSTEMI STEMI ) admission Drugs high risk long QT interval torsade de pointes ( amiodarone , flecainide , procainamide , sotalol , droperidol , haldol , citalopram , macrolides ) Documented uncorrected severe hypokalemia ( K+ &lt; 3.0 mmol/L ) hypomagnesemia ( Mg2+ &lt; 0.5 mmol/L ) Chronic systemic steroid ( &gt; 4 mg methylprednisolone /day â‰¥ 2 month ) Actual use macrolides least 2 week Allergy macrolides Active cancer treatment Life expectancy &lt; 3 month Pregnant breastfeeding subject . Woman childbearing potential must pregnancy test perform negative result must document start treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AECOPD</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Acute exacerbation</keyword>
	<keyword>Hospitalization</keyword>
	<keyword>Azithromycin</keyword>
	<keyword>Macrolides</keyword>
	<keyword>Randomized Controlled Trial</keyword>
	<keyword>Placebo</keyword>
</DOC>